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Abstract
Purpose This Phase I, multicenter, randomized study
(ClinicalTrials.gov NCT01220128) evaluated the safety
and immunogenicity of recombinant Wilms’ tumor 1
(WT1) protein combined with the immunostimulant AS15
(WT1-immunotherapeutic) as neoadjuvant therapy admin-
istered concurrently with standard treatments in WT1-
positive breast cancer patients.
Methods Patients were treated in 4 cohorts according to
neoadjuvant treatment (A: post-menopausal, hormone
receptor [HR]-positive patients receiving aromatase inhi-
bitors; B: patients receiving chemotherapy; C: HER2-
overexpressing patients on trastuzumab–chemotherapy
combination; D: HR-positive/HER2-negative patients on
chemotherapy). Patients (cohorts A–C) were randomized
(2:1) to receive 6 or 8 doses of WT1-immunotherapeutic or
placebo together with standard neoadjuvant treatment in a
double-blind manner; cohort D patients received WT1-
immunotherapeutic in an open manner. Safety was asses-
sed throughout the study. WT1-specific antibodies were
assessed pre- and post-vaccination.
Results Sixty-two patients were randomized; 60 recei-
ved C one dose of WT1-immunotherapeutic. Two severe
toxicities were reported: diarrhea (cohort C; also reported
as a grade 3 serious adverse event) and decreased left
ventricular ejection fraction (cohort B; also reported as a
grade 2 adverse event). Post-dose 4 of WT1-immunother-
apeutic, 10/10 patients from cohort A, 0/8 patients from
cohort B, 6/11 patients from cohort C, and 2/3 patientsElectronic supplementary material The online version of this
article (doi:10.1007/s10549-017-4130-y) contains supplementary
material, which is available to authorized users.
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from cohort D were humoral responders. The sponsor
elected to close the trial prematurely.
Conclusions Concurrent administration of WT1-im-
munotherapeutic and standard neoadjuvant therapy was
well tolerated and induced WT1-specific antibodies in
patients receiving neoadjuvant aromatase inhibitors. In
patients on neoadjuvant chemotherapy or trastuzumab–
chemotherapy combination, the humoral response was
impaired or blunted, likely due to either co-administration
of corticosteroids and/or the chemotherapies themselves.
Keywords Breast cancer  Immunotherapy  Neoadjuvant
therapy  WT1 antigen  Immunogenicity  Safety
Introduction
Immunotherapies are rapidly becoming standard of care for
many solid tumors. In the last 5 years, ipilimumab, pem-
brolizumab, and nivolumab have been approved for many
cancer types [1–4]. There is an evolving interest in the
immunogenicity of breast tumors and the possible role of
immunotherapy in this common cancer [5, 6]. Various
immunotherapeutic strategies, including checkpoint inhibitors,
vaccines, adoptive T-cell transfer, or cytokine therapy, have
been tested for treatment of breast cancer (BC) [6, 7]. Vaccines
constitute an attractive immunotherapy approach aiming to
stimulate the intrinsic antitumor immune response by present-
ing tumor antigens recognized by T-cells. Wilms’ tumor 1
(WT1) is a potential target antigen for cancer immunotherapy
as it is over-expressed in the majority of solid tumors [8–12].
Owing to its specificity, oncogenicity, immunogenicity, and
therapeutic function, WT1 has been classified as one of the most
promising targets for cancer immunotherapy [13]. WT1 plays
an oncogenic role in BC and is expressed in approximately 33%
(range: 3–48.5%) of malignant breast tumors [11, 14–16].
Additionally, high WT1 levels have previously been correlated
with poorer outcomes in BC [15, 17].
Combining chemotherapy with immune-based interven-
tions has great potential for optimizing clinical outcomes of
BC patients. This study evaluated the safety, immuno-
genicity, and preliminary clinical activity of the WT1 anti-
gen combined with GSK’s proprietary immunostimulant
AS15 (WT1-immunotherapeutic) administered to women
with BC during standard neoadjuvant treatment.
Patients and methods
Study design and patients
This study was an international, multicenter, double-blind,
randomized, placebo-controlled, Phase I/II clinical trial
conducted between 2011 and 2014 in 19 medical centers in
Belgium, France, Germany, Italy, the Russian federation,
the United Kingdom, and the United States. Phase I ini-
tially included three parallel cohorts (A, B, and C), in
which patients were randomized in a double-blind manner
(2:1) to receive six or eight doses of WT1-immunothera-
peutic (WT1 groups) or placebo (placebo groups) at
3-week intervals, together with the standard neoadjuvant
treatment (Fig. S1).
The neoadjuvant treatment was chosen according to
institutional standards, based on the hormone receptor
(HR) and human epidermal growth factor receptor-2
(HER2) status of the tumor. Cohort A received daily aro-
matase inhibitors (AIs) for 18 or 24 weeks of neoadjuvant
treatment; cohorts B and C received WT1-immunothera-
peutic/placebo on the same day as chemotherapy (Fig. S2),
with patients in cohort C also receiving trastuzumab. Fur-
ther recruitment beyond Phase I in each cohort depended
on the outcome of intermediate assessment of the induced
WT1-specific antibody response. Only if a C40% response
rate (based on post-dose 4 WT1-specific antibody respon-
ses in at least six patients in the WT1 group) was achieved,
and provided no safety issues were identified, would the
cohort proceed to Phase II.
Following the analysis of early immunogenicity results
in cohort B (see Results section), a further cohort (D) was
opened to investigate an alternative dosing schedule
(Fig. S1). Cohort D received WT1-immunotherapeutic on
day 14 of each 3-weekly chemotherapy cycle in an open-
label manner (Fig. S2).
Patients aged C18 years with WT1-positive, histologi-
cally confirmed, primary invasive BC were eligible for
enrollment. Details of inclusion/exclusion criteria, as well
as study treatment and administration, study procedures,
data collection, and blood sampling are included in Sup-
plementary materials.
All patients provided written informed consent before
any study-related procedures. The study was conducted in
accordance with Good Clinical Practice and all applicable
regulatory requirements, including the Declaration of
Helsinki. The protocol was approved by the national
independent ethics committees and institutional review
boards of the study centers. The study was registered at
www.ClinicalTrials.gov (NCT01220128). A protocol
summary is available at http://www.gsk-clinicalstudyr
egister.com (GSK study ID 113172).
Objectives
Phase I study objectives were the evaluation of safety and
immunogenicity of WT1-immunotherapeutic as neoadju-
vant therapy administered concurrently with different
standard treatments.
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Phase II objectives included further assessment of safety
and immunogenicity, and a preliminary assessment of the
clinical activity of WT1-immunotherapeutic in combina-
tion with standard neoadjuvant treatments, i.e., pathologi-
cal complete response (pCR) rate, disease free survival
(DFS), and overall survival (OS); of note, due to early
termination of the trial, the analysis of DFS and OS out-
comes was not performed.
Safety and immunogenicity assessments
Adverse events (AEs), including severe toxicities (defined
in Supplementary materials), and serious adverse events
(SAEs) were assessed throughout the study.
WT1-specific antibodies were measured by an enzyme-
linked immunosorbent assay (ELISA). WT1-specific
humoral response was defined as the appearance of anti-
bodies for baseline seronegative patients, or an at least
2-fold increase in antibody concentrations for baseline
seropositive patients. The ELISA assay cut-off was 9
ELISA units (EU)/ml.
Clinical activity assessment
pCR, i.e., complete response (CR) or partial response (PR)
in the breast and axillary nodes was assessed at the
definitive surgery. pCR in the primary tumor was evaluated
according to the Miller/Payne grading system [18], and in
lymph nodes, by histopathological examination. The ref-
erence pCR rates based on the reported in literature rates
under standard treatment for a given patient population
were: 5% for cohort A (based on a 3–5% rate), 20% for
cohort B (6–30%), and 50% for cohort C (30–65%) (see
details in Supplementary materials).
Statistical analyses
Statistical analyses were performed using Statistical
Analysis Systems (SAS) Drug and Development with SAS
version 9.2.
The total treated cohort (TTC) included all patients who
received at least one dose of WT1-immunotherapeu-
tic/placebo. The according-to-protocol (ATP) cohort for
immunogenicity included all eligible patients (i.e., those
meeting all eligibility criteria for enrollment), who did not
report major protocol deviation, who received at least the
first four doses of WT1-immunotherapeutic/placebo, and
who provided a valid result for immunogenicity measure-
ment within four weeks of post-dose 4 (visit 5). Data col-
lected after major protocol violation were eliminated from
ATP immunogenicity analyses.
Descriptive analyses of demographics and baseline
characteristics were performed on the TTC. Safety analyses
were performed on the TTC, and immunogenicity analyses
on the ATP cohort for immunogenicity.
Results
Study patients
Phase I recruitment was completed in March 2013 for
cohort A, November 2011 for cohort B, and June 2012 for
cohort C. Phase II recruitment for cohort A had been ini-
tiated as the protocol criteria were met, but was stopped
prematurely in July 2014, following the sponsor’s decision.
Enrollment in cohort B did not proceed to the Phase II
segment because the protocol-defined immune response
success (C40% of patients showing a humoral response)
was not fulfilled. In cohort C, weak immune responses with
antibody concentrations close to the assay cut-off values
were induced in only a few patients (see Immunogenicity
section below) and, although meeting the protocol criteria
of success, these immune responses were considered sub-
optimal; therefore, Phase II for this cohort was not initi-
ated. Recruitment of cohort D patients was also stopped
prematurely at the same time as the Phase II for cohort A.
In total, 366 patients were screened for WT1 expression;
127 (34.7%) had WT1-positive tumors. Sixty-two patients
were randomized and 60 were treated (cohort A: 22, B: 15,
C: 15, D: 8); 47 patients completed the treatment (Fig. 1).
The majority of patients (95.0%) were of Caucasian
origin; the median age (range) of the patients in WT1 and
placebo groups was 72.0 (54–84) and 74.0 (60–80) years in
cohort A, 41.0 (37–77) and 62.5 (48–74) years in cohort B,
52 (38–69) and 53.0 (46–61) years in cohort C, respec-
tively, and 47 (42–69) years in cohort D (WT1 group only).
The majority of patients enrolled had Stage IIA (38.3%) or
IIB (38.3) tumors; 13.3% had Stage IIIA, 8.3%, Stage IIIB,
and 1.7%, Stage IIIC tumors.
Safety
Two severe toxicities were reported: diarrhea (cohort C;
also reported as a grade 3 SAEs) and decreased left ven-
tricular ejection fraction (cohort B; also reported as a grade
2 AE).
Grade 3 AEs considered by the investigator to be
related/possibly related to WT1-immunotherapeutic
administration were reported by one patient in cohort A
(headache, two separate events) and one patient in cohort C
(diarrhea); the latter was also reported as a SAE and as a
severe toxicity event (Table 1).
Thirty-seven SAEs were reported by 20 patients
(Table 1); two were considered by the investigators to be
related/possibly related to WT1-immunotherapeutic
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administration: grade 2 polymyalgia rheumatica (cohort A;
also reported as potential immune-mediated disorder) and
diarrhea (mentioned above).
Two patients (WT1 group, cohort B) died during the
study. One patient died due to an unknown cause, possibly
due to underlying medical conditions of hypertension and
thrombosis; this fatal SAE was assessed by the investiga-
tors as not causally related to WT1-immunotherapeutic
administration. The second patient died due to progressive
BC.
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Fig. 1 Participant flow N, number of patients; WT1 patients who
received WT1-immunotherapeutic; ATP cohort, according-to-proto-
col cohort for immunogenicity; SAE serious adverse event; pIMD
potential immune-mediated disease; PD progressive disease; Cohort
A: post-menopausal patients with hormone receptor-positive breast
cancer receiving AIs as neoadjuvant therapy; Cohort B: patients
receiving neoadjuvant chemotherapy; Cohort C: patients with human
epidermal growth factor receptor-2 (HER-2)-overexpressing breast
cancer receiving neoadjuvant trastuzumab therapy combined with
chemotherapy; Cohort D: patients with hormone receptor-positive/
HER2-negative breast cancer receiving neoadjuvant chemotherapy;
patients in cohort D received WT1-immunotherapeutic in an open-
label manner
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The Data Safety Monitoring Committee reviewed safety
data every six months during the trial, with the last review
in June 2015, and did not identify any potential safety
issues.
Immunogenicity
At baseline, all patients were seronegative for WT1-
specific antibodies; post-dose 4, all 10 patients from cohort
A (100%), 0/8 patients (0.0%) from cohort B, 6/11 (54.5%)
patients from cohort C, and 2/3 (66.7%) patients from
cohort D were humoral responders.
The highest WT1-specific antibody levels were
observed in cohort A, in which patients received AIs as
concomitant standard treatment (Fig. 2a). No antibody
response was observed in cohort B receiving concomitant
chemotherapy (Fig. 2b), while in cohorts C and D, weak
WT1-specific antibody responses were only observed in
some patients (Fig. 2c–d).
Of note, different types of antibody responses were
observed in cohort C, with some patients presenting no
antibody response (similar to cohort B), some having a
delayed response, and others, immediate antibody titer
development. WT1-specific antibody titers of patients from
cohort C who developed an immune response were around
1 log below the results obtained in cohort A. Patients from
cohort C who were immediate antibody responders
received docetaxel, carboplatin, and trastuzumab (TCH) as
concomitant chemotherapy. In cohort B, nearly all patients
received sequential chemotherapy, starting with the com-
bination of anthracyclines/cyclophosphamide and finishing
with taxane-based therapy (paclitaxel or docetaxel).
Patients in cohort C with no or a delayed immune response
received the same treatment combination as in cohort B
with the addition of trastuzumab.
No conclusions could be drawn for cohort D, as anti-
body responses were evaluated for only 3/8 patients
enrolled in TTC due to the early termination of the study;
two of these patients showed positive responses within the
same range as those observed in cohort C.
Clinical activity
The clinical activity was evaluated in 51 patients and is
shown by treatment group in Table 2. In cohort A, among
the 18 evaluable patients, seven patients had PR and 11 had
no response. Among 15 patients in cohort B, two had pCR,
eight had PR, and five patients had no response. Of the ten
evaluable patients in cohort C, nine had pCR, four had PR,
and one patient had no response. Among the four patients
from cohort D who received WT1-immunotherapeutic in
an open manner, one had pCR and three had PR.
Discussion
The role of the host immune response to the tumor in BC
has long been debated as, compared to melanoma or renal
cell carcinoma, BC has been considered less immunogenic.
However, current data suggest that BC, particularly the
more aggressive subtypes of HER2-positive and triple-
negative BC, can elicit host antitumor immune responses,
and that the robustness of the response correlates with
prognosis [5, 19–21]. The concept of natural
Table 1 Overall incidence of AEs and SAEs (total treated cohort)























Any 15 (100) 5 (71) 9 (100) 6 (100) 11 (100) 4 (100) 7 (88)
Grade 3–5b 3 (20) 0 (0) 3 (33) 6 (100) 7 (64) 1 (25) 5 (63)
Related/possibly relatedc 12 (80) 2 (29) 3 (33) 0 (0) 7 (64) 1 (25) 6 (75)
Grade 3 related/possibly relatedd 1 (7) 0 (0) 0 (0) 0 (0) 1 (9) 0 (0) 0 (0)
SAEs 3 (20) 0 (0) 4 (44) 2 (33) 5 (45) 1 (25) 5 (63)
a Patients in cohort D received WT1-immunotherapeutic in an open-label manner
b AEs of grade 3 or higher intensity
c AEs considered by the investigator to be related or possibly related to WT1-immunotherapeutic/placebo administration
d AEs of grade 3 intensity considered by the investigator to be related or possibly related to WT1-immunotherapeutic/placebo administration
WT1 WT1-immunotherapeutic; AEs adverse events; SAEs serious adverse events; N, number of patients; n (%), number (percentage) of patients
reporting at least once the AE




























Fig. 2 Pre- and post-immunization WT1-specific antibody titers in
patients from a cohort A, b cohort B, c cohort C, and d cohort D (ATP
cohort for immunogenicity). ATP according-to-protocol; EU/ml,
ELISA units per ml (antibody concentration). The cut-off of the
ELISA assay was 9 EU/ml. The color lines correspond to individual
patients’ antibody titers at indicated timepoints
Table 2 Overall pathological
response rates (total treated
cohort)
0 No response Partial response pCR pCR ratea










A (N = 19) WT1 (N = 13) 6 (50.0) 2 (16.7) 4 (33.3) 0 (0.0) 0 (0.0) 3–5%
8 (66.7) 4 (33.3)
Placebo (N = 6) 2 (33.3) 1 (16.7) 3 (50.0) 0 (0.0) 0 (0.0)
3 (50.0) 3 (50.0)
B (N = 15) WT1 (N = 9) 4 (44.4) 0 (0.0) 4 (44.4) 1 (11.1) 0 (0.0) 6–30%
4 (44.4) 5 (55.6)
Placebo (N = 6) 0 (0.0) 1 (16.7) 3 (50.0) 0 (0.0) 2 (33.3)
1 (16.7) 3 (50.0)
C (N = 15) WT1 (N = 11) 0 (0.0) 1 (10.0) 1 (10.0) 2 (20.0) 6 (60.0) 30–65%
1 (10.0) 3 (30.0)
Placebo (N = 4) 0 (0.0) 0 (0.0) 1 (25.0) 0 (0.0) 3 (75.0)
0 (0.0) 1 (25.0)
D (N = 4)b WT1 0 (0.0) 0 (0.0) 2 (50.0) 1 (25.0) 1 (25.0)
0 (0.0) 3 (75.0)
a pCR rate: pCR rate under standard treatment for a given patient population reported in literature
b All patients in cohort D received WT1-immunotherapeutic in an open-label manner
N number of patients; pCR pathological complete response; n number of patients in a given category; %,
n/number of patients with available results 9 100
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immunogenicity of BC is based on the presence of tumor-
infiltrating lymphocytes (TILs) and other immune cells
within the tumor microenvironment, on the prognostic
value of immune-related gene signatures, and the fre-
quency of genetic instability which leads to higher numbers
of somatic mutations and neoantigens [5, 22]. Additionally,
the pre-existing immunologic response might enhance the
effects of conventional chemotherapy [5, 23].
In cohort A, all patients who received WT1-im-
munotherapeutic developed WT1-specific antibodies. The
antibody titers obtained in this cohort can be considered as
reference titers, as only in this cohort patients did not
receive chemotherapy or routine corticosteroids. In con-
trast, none of the patients receiving WT1-immunothera-
peutic in cohort B developed antibodies. Analysis of B-cell
population dynamics revealed depletion of B-cells in these
patients compared to healthy donors, either due to the
chemotherapy itself or the corticosteroids which are rou-
tinely used as anti-emetics in patients receiving
chemotherapy (data not shown). The impact of cancer
treatments on all lymphocytic populations, especially
B-cells, has been previously described [24–26]. A study in
BC patients evaluating the effects of combination
chemotherapy regimens with epirubicin (5-fluorouracil,
epirubicin, cyclophosphamide) versus doxorubicin (5-flu-
orouracil, doxorubicin, cyclophosphamide) on immune
cells, revealed an increase in cytotoxic T-cell levels and
natural killer cell levels, and a dramatic decrease in B-cell
levels in the blood following in either regimen [26]. Nev-
ertheless, the lympho-depleting effects induced by
chemotherapy are transient and soon after drug discontin-
uation, a homeostatic rebound overshoot of the lympho-
cytic pool occurs [24].
In cohort C, a mix of titer profiles was observed, sup-
porting the hypothetic blunting effect of chemotherapy co-
administered on day 1, and also suggesting that different
chemotherapy agents may have differing immunosuppres-
sive effects. Diverse myelosuppressive effects of specific
chemotherapeutic agents have been previously reported
[27–29].
Another parameter difficult to discriminate from the
chemotherapy effect is the impact of co-administered
corticosteroids which were allowed per protocol for the
prevention and treatment of chemotherapy-related nausea
and hypersensitivity reactions. In cohort C, patients
received trastuzumab co-administered with chemotherapy,
and in numerous cases, patients receiving chemotherapy
also received corticosteroids.
The traditional paradigm that chemotherapeutic agents
suppress immune response has been challenged by evi-
dence that chemotherapy induces, and is dependent upon
activation of certain immunologic effects and may promote
immune-mediated tumor destruction [30–33]. TILs within
breast tumors have been shown to correlate with pCR and
clinical response to neoadjuvant chemotherapy [34, 35].
The possible immunomodulatory mechanisms involving
trastuzumab include inhibition of HER2-mediated signal-
ing and antibody-dependent cell-mediated cytotoxicity
[36, 37]. The AI anastrozole was shown to alter the
proinflammatory cytokine levels and suppressed differen-
tiation of naive T-cells into regulatory T-cells, which are
known to produce immunosuppressive cytokines in the
tumor microenvironment [38, 39].
An additional cohort D received WT1-immunothera-
peutic on day 14 of each chemotherapy cycle, to evaluate
if delaying the immunotherapy administration after the
chemotherapy treatment improves the immune response.
Day 14 was selected because corticosteroids were not
administered on that day and patients were expected to
have passed their white cell count nadir. In a study with
MAGE-A3 immunotherapeutic in non-small cell lung
cancer patients who received concurrent cisplatin/vi-
norelbine chemotherapy regimen, a robust MAGE-A3-
specific antibody response was induced in all patients
[40]. However, in this previous study, MAGE-A3
immunotherapeutic was administered on day 8 of each
chemotherapy cycle, whereas in cohort B of the current
study, chemotherapy was administered on the same day as
WT1-immunotherapeutic. This information also rein-
forced the hypothesis of a differential impact of the
chemotherapy types on the immune response. Although
our study was stopped before finalization of enrollment in
cohort D, from the few data collected, it is apparent that
delaying administration of immunotherapy (14 days fol-
lowing the chemotherapy cycle initiation) did not improve
the immunogenicity, as antibody titers obtained in cohort
D were similar to those obtained in cohort C. In one
patient from cohort D, the sequence of chemotherapy was
reversed, starting with docetaxel followed by epiru-
bicin/cyclophosphamide combination. In this patient, the
WT1-specific antibody level rose immediately while the
patient underwent docetaxel chemotherapy, but fell
thereafter following epirubicin/cyclophosphamide treat-
ment. Altogether, these data suggest that concomitant
corticosteroid administration and/or possibly specific
chemotherapies (particularly anthracycline combinations)
impacted the WT1-specific antibody generation post-
vaccination.
Limitations of our study include the presence of multiple
confounding factors and small numbers of patients in each
cohort.
In conclusion, concurrent administration of WT1-im-
munotherapeutic and standard therapy was well tolerated
and induced WT1-specific antibody response in BC
patients when co-administered with neoadjuvant AIs. In
patients on neoadjuvant chemotherapy or a trastuzumab–
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chemotherapy combination, the humoral response was
impaired or blunted, likely due to either co-administration
of corticosteroids and/or the chemotherapies themselves.
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